Population In Vitro-In Vivo Correlation Model Linking Gastrointestinal Transit Time, pH, and Pharmacokinetics: Itraconazole as a Model Drug
To establish an in vitro-in vivo correlation (IVIVC) model for Sporanox and SUBA-itraconazole formulations and to understand the impact of gastrointestinal (GI) pH and transit times on itraconazole dissolution and absorption.
IVIVC was developed based on fed/fasted pharmacokinetic data from randomized cross-over trials, in vitro dissolution studies, and prior information about typical and between subject variability of GI pH and transit times. Data were analysed using the population modelling approach as implemented in NONMEM.
Dissolution kinetics were described using first order models. The in vivo pharmacokinetics of itraconazole was described with a 2-compartment model with 4-transit absorption compartments. Pharmacokinetic profiles for fasted itraconazole periods were described based on the in vitro dissolution model, in vivo disposition model, and the prior information on GI pH and transit times. The IVIVC model indicated that drug dissolution in the fed state required an additional pH-independent dissolution pathway. The IVIVC models were presented in a ‘Shiny’ application.
An IVIVC model was established and internally evaluated for the two itraconazole formulations. The IVIVC model provides more insight into the observed variability of itraconazole pharmacokinetics and indicated that GI pH and transit times influence in vivo dissolution and exposure.
KEY WORDSin vitro- in vivo correlation itraconazole NONMEM population pharmacokinetic
Akaike information criteria
Area under the concentration-time curve
Biopharmaceutics classification system
Gastrointestinal transit time
High performance liquid chromatography
In vitro-in vivo correlation
Minimum objective function value
Model event time
Non-linear mixed effect modelling
Visual predictive check
ACKNOWLEDGMENTS AND DISCLOSURES
All the pharmacokinetic studies used in the analysis were sponsored by Mayne Pharma International. S.M and D.H are employees at Mayne Pharma. R.U. has acted as a paid consultant for Mayne Pharma International. The Australian Centre for Pharmacometrics is an initiative of the Australian Government as part of the National Collaborative Research Infrastructure Strategy. A.Y.A is a PhD student receiving an Endeavour Scholarship funded by the Department of Education and Training of the Australian Government (Scholarship ID no. 4088).
- 5.Abuhelwa AY, Foster DJ, Mudge S, Hayes D, Upton RN. Population pharmacokinetic modelling of itraconazole and hydroxyl-itraconazole for oral SUBA-itraconazole and Sporanox capsule formulations in healthy subjects in fed and fasted states. Antimicrob Agents Chemother. 2015.Google Scholar
- 9.Janssen Pharmaceuticals Inc. Sporanox (itraconazole) capsules. Janssen Pharmaceuticals Inc, Beers, Belgium.Google Scholar
- 10.Beal S, Sheiner LB, Boeckmann A, Bauer RJ. NONMEM user’s guides, part V. (1989–2009). Ellicott City: Icon Development Solutions; 2009.Google Scholar
- 11.R Core Team. R: a language and environment for statistical computing Vienna, Austria R Foundation for Statistical Computing; 2014.Google Scholar
- 14.Wickham H. Scales: Scale functions for graphics: CRAN.R-project.org; 2014.Google Scholar
- 26.RStudio Inc. Shiny: web application framework for R. R package version 0.10.1. http://CRAN.R-project.org/package=shiny2015.
- 34.Food and Drug Administration. Guidance for industry: extended release oral dosage forms: development, evaluation, and application of in vitro/in vivo correlations. Center for Drug Evaluation and Research, Rockville. 1997.Google Scholar
- 35.Mayne Pharma International Pty Ltd. Lozanoc® (Itraconazole) 50 mg capsules: consumer medicine information. Available from: https://www.betterhealth.vic.gov.au/~/media/bhc/files/medicine%20guides%20library/11/cmi11099.pdf.
- 38.Lu PJ, Hsu PI, Chen CH, Hsiao M, Chang WC, Tseng HH, et al. Gastric juice acidity in upper gastrointestinal diseases. World J Gastroenterol. 16(43):5496–501.Google Scholar